Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Johnson & johnson save search
Sonnet BioTherapeutics Announces an Agreement with Janssen for the Evaluation of Three Sonnet Product Candidates
Published: 2022-10-31 (Crawled : 14:20) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
SONN | $1.84 3.96% 3.8% 22K
|
Health Technology
|
| O: 18.97%
H: 95.65%
C: 39.86%
agreement
IGM Biosciences Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Published: 2022-03-29 (Crawled : 11:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
IGMS | $7.2 -2.83% -2.92% 220K
|
Health Technology
|
| O: 42.23%
H: 68.76%
C: 38.32%
results
Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis
Published: 2023-03-07 (Crawled : 14:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.34%
H: 0.1%
C: -1.28%
PTGX | $25.61 1.55% 1.52% 450K
|
Health Technology
|
| O: 11.64%
H: 39.6%
C: 36.06%
il-23 topline trial therapeutics psoriasis frontier positive
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
Published: 2022-04-20 (Crawled : 12:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 1.17%
H: 0.68%
C: 0.27%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 1.06%
H: 1.14%
C: 0.91%
ARCT 4 | $25.995 -1.23% -1.25% 630K
|
Health Technology
|
| O: -20.04%
H: 28.04%
C: 21.44%
covid-19 arct-154 vaccine mrna phase 3
Biopharma Layoff Tracker 2024: Novavax, 2seventy Bio, Catamaran Bio and More Cut Staff
Published: 2024-01-31 (Crawled : 16:00) - biospace.com/
MPSYF | $70.28 -71.33% 110
|
Health Technology
|
| O: -2.2%
H: 0.19%
C: -1.34%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.49%
H: 0.14%
C: -0.94%
VXRT | $0.7652 -9.15% -10.08% 1.9M
|
Health Technology
|
| O: 4.08%
H: 27.45%
C: 15.69%
TXMD | $1.86 -1.59% -1.61% 10K
|
Health Technology
|
| O: -0.99%
H: 2.2%
C: -0.44%
PTCT | $25.32 2.55% 2.49% 3.9M
|
Health Technology
|
| O: -0.15%
H: 3.13%
C: -1.62%
NKTR | $1.265 -4.17% -4.35% 4.7M
|
Health Technology
|
| O: -3.0%
H: 3.06%
C: -0.17%
MOR | $17.96 -0.5% -0.5% 180K
|
Health Technology
|
| O: -1.56%
H: 2.8%
C: -1.96%
AMRN | $0.88 0.94% 0.93% 1M
|
Health Technology
|
| O: -0.81%
H: 0.0%
C: -8.13%
GOOGL | News S | $154.08 -1.24% -1.25% 32M
|
Technology Services
|
| O: -5.18%
H: 0.26%
C: -2.45%
GOOG | News S | $155.7 -1.12% -1.13% 20M
|
Technology Services
|
| O: -5.0%
H: 0.14%
C: -2.47%
OCX J | $2.495 -2.54% -2.61% 50K
|
Health Technology
|
| O: 0.99%
H: 2.62%
C: 1.64%
biopharma
Europe Frontotemporal Dementia Market Research Report 2023: Growing Prevalence of Dementia & Increasing Number of Clinical Trials - Competition, Forecasts & Opportunities to 2028
Published: 2023-04-26 (Crawled : 15:20) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -4.57%
H: 0.22%
C: -1.98%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
VTRS | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 0.22%
H: 0.65%
C: -1.09%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.62%
H: 0.0%
C: -2.04%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.66%
H: 0.18%
C: -0.9%
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.03%
H: 0.3%
C: -2.63%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.53%
H: 0.0%
C: 0.0%
CNTG | $0.463 0.43% 0.43% 79K
|
Commercial Services
|
| O: 1.23%
H: 27.27%
C: -15.76%
europe report dementia trials research growing market
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-28 (Crawled : 12:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.67%
H: 0.0%
C: 0.0%
MRSN | $3.255 -2.55% -2.61% 2.4M
|
Health Technology
|
| O: -5.39%
H: 24.13%
C: 20.05%
business year update therapeutics financial results
Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi
Published: 2023-10-19 (Crawled : 12:00) - globenewswire.com
PPRUF | News | $358.55 37.56% 1.5K
|
Consumer Non-Durables
|
| O: -0.57%
H: 1.09%
C: 0.98%
PPRUY | News | $36.0023 -0.11% 220K
|
Manufacturing
|
| O: 1.4%
H: 0.53%
C: -0.81%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.73%
H: 0.0%
C: 0.0%
RPRX | $28.17 1.0% 0.99% 1.8M
|
Health Technology
|
| O: 0.15%
H: 3.45%
C: 2.22%
PTCT | $25.32 2.55% 2.49% 3.9M
|
Health Technology
|
| O: 3.46%
H: 19.19%
C: 11.13%
pharma royalty evrysdi agreement
Biopharma Layoff Tracker 2023: SQZ, Regenxbio, Lyell and More Cut Staff
Published: 2023-11-09 (Crawled : 17:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.22%
H: 0.0%
C: 0.0%
VXRT | $0.7652 -9.15% -10.08% 1.9M
|
Health Technology
|
| O: 0.0%
H: 1.54%
C: -3.72%
TXMD | $1.86 -1.59% -1.61% 10K
|
Health Technology
|
| O: -0.91%
H: 2.52%
C: -8.26%
PTCT | $25.32 2.55% 2.49% 3.9M
|
Health Technology
|
| O: 0.61%
H: 0.0%
C: -5.07%
NKTR | $1.265 -4.17% -4.35% 4.7M
|
Health Technology
|
| O: 6.68%
H: 0.0%
C: -10.95%
MOR | $17.96 -0.5% -0.5% 180K
|
Health Technology
|
| O: 2.3%
H: 0.12%
C: -7.22%
AMRN | $0.88 0.94% 0.93% 1M
|
Health Technology
|
| O: 0.75%
H: 2.04%
C: -3.48%
GOOGL | News S | $154.08 -1.24% -1.25% 32M
|
Technology Services
|
| O: 0.2%
H: 0.0%
C: 0.0%
GOOG | News S | $155.7 -1.12% -1.13% 20M
|
Technology Services
|
| O: 0.16%
H: 0.0%
C: 0.0%
OCX J | $2.495 -2.54% -2.61% 50K
|
Health Technology
|
| O: 15.38%
H: 18.13%
C: 12.42%
biopharma
Hydrogel-based Drug Delivery System Market Size Worth $10.6 Billion By 2028: Grand View Research, Inc.
Published: 2021-07-21 (Crawled : 10:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.5%
H: 0.23%
C: 0.11%
OCUL | News | $5.22 -10.92% -12.26% 9.1M
|
Health Technology
|
| O: 0.81%
H: 2.09%
C: 1.77%
ENDP | $0.2926 -9.6%
|
Health Technology
|
| O: 1.67%
H: 18.07%
C: 10.8%
drug research drug delivery liver
Biopharma Layoff Tracker 2023: Atreca, Pfizer, Orbital and More Cut Staff
Published: 2023-11-15 (Crawled : 16:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.15%
H: 0.0%
C: 0.0%
VXRT | $0.7652 -9.15% -10.08% 1.9M
|
Health Technology
|
| O: -2.04%
H: 17.99%
C: 12.69%
TXMD | $1.86 -1.59% -1.61% 10K
|
Health Technology
|
| O: 0.0%
H: 17.91%
C: 17.41%
PTCT | $25.32 2.55% 2.49% 3.9M
|
Health Technology
|
| O: -0.3%
H: 7.1%
C: 2.47%
NKTR | $1.265 -4.17% -4.35% 4.7M
|
Health Technology
|
| O: -0.96%
H: 6.91%
C: 3.94%
MOR | $17.96 -0.5% -0.5% 180K
|
Health Technology
|
| O: -0.94%
H: 2.53%
C: -6.21%
AMRN | $0.88 0.94% 0.93% 1M
|
Health Technology
|
| O: -1.56%
H: 6.55%
C: 1.34%
GOOGL | News S | $154.08 -1.24% -1.25% 32M
|
Technology Services
|
| O: 0.5%
H: 0.12%
C: -0.19%
GOOG | News S | $155.7 -1.12% -1.13% 20M
|
Technology Services
|
| O: 0.72%
H: 0.15%
C: -0.19%
OCX J | $2.495 -2.54% -2.61% 50K
|
Health Technology
|
| O: 1.5%
H: 17.99%
C: 16.81%
biopharma
Silk Road Medical Names Chas McKhann Chief Executive Officer
Published: 2023-11-02 (Crawled : 12:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
SILK | $17.32 -0.57% -0.58% 370K
|
Health Technology
|
| O: 1.08%
H: 16.69%
C: 10.55%
medical
Vaxcyte Reports First Quarter 2021 Financial Results and Provides Business Update
Published: 2021-05-11 (Crawled : 21:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.2%
H: 0.75%
C: -0.2%
PCVX | $60.82 0.33% 0.33% 1.3M
|
Health Technology
|
| O: -1.9%
H: 16.11%
C: 9.76%
financial results results
Janssen Steps Away from Phase I Prostate Cancer Study, Cites Patient Enrollment Issues
Published: 2022-10-31 (Crawled : 17:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
EPIX | $6.57 -2.23% -2.28% 100K
|
Health Technology
|
| O: -27.44%
H: 15.0%
C: 12.5%
cancer prostate cancer
Janssen Steps Away from Phase I Prostate Cancer Study, Cites Patient Enrollme...
Published: 2022-10-31 (Crawled : 18:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
EPIX | $6.57 -2.23% -2.28% 100K
|
Health Technology
|
| O: -27.44%
H: 15.0%
C: 12.5%
cancer prostate cancer
Enlivex Announces Second Quarter 2022 Financial Results and Provides a Business Update
Published: 2022-08-22 (Crawled : 13:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 1.1%
H: 0.0%
C: 0.0%
ENLV | $1.4 -4.23% 110K
|
Health Technology
|
| O: -6.84%
H: 14.26%
C: 10.9%
update results
Hematopoietic Stem Cell Transplantation Market to Grow Rapidly During the Study Period (2019-2032), Evaluates DelveInsight
Published: 2024-01-08 (Crawled : 22:00) - prnewswire.com
INAB | $1.0 -4.76% -5.0% 280K
|
|
| O: 2.67%
H: 13.64%
C: 9.74%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
MCRB | $0.5671 -2.93% -3.02% 3.7M
|
Health Technology
|
| O: 26.92%
H: 3.54%
C: -27.78%
DTIL | $9.75 -9.05% -9.95% 170K
|
Health Technology
|
| O: 10.0%
H: 14.23%
C: 0.09%
OMER | $3.045 -5.14% -5.42% 390K
|
Health Technology
|
| O: -0.56%
H: 13.38%
C: 11.27%
MRKR | $4.25 3.65% 3.52% 15K
|
Consumer Services
|
| O: 1.21%
H: 0.0%
C: -0.8%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.0%
H: 0.53%
C: -2.19%
cell study market
Adverum Biotechnologies Announces New Executive Leadership Roles
Published: 2023-05-25 (Crawled : 11:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.39%
H: 0.15%
C: -1.05%
ADVM | $11.34 1.7% 1.68% 140K
|
Health Technology
|
| O: -1.54%
H: 14.2%
C: 9.09%
Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined With a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)
Published: 2021-07-08 (Crawled : 12:15) - globenewswire.com
VOR | $1.71 1.79% 1.75% 200K
|
|
| O: -0.77%
H: 13.83%
C: 9.88%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.42%
H: 0.45%
C: 0.23%
biopharma myeloid leukemia stem cell therapy collaboration announces collaboration antibody leukemia acute myeloid leukemia aml
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024
Published: 2024-02-15 (Crawled : 13:00) - biospace.com/
MURA | $3.55 -0.56% -0.56% 240K
|
|
| O: 2.78%
H: 8.11%
C: 3.53%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.19%
H: 1.6%
C: 1.24%
ALKS | $23.86 0.42% 0.42% 2.4M
|
Health Technology
|
| O: 2.72%
H: 13.77%
C: 13.25%
year financial results
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.